Skip to main content
. Author manuscript; available in PMC: 2015 Oct 24.
Published in final edited form as: Cancer Prev Res (Phila). 2012 Feb 7;5(4):603–611. doi: 10.1158/1940-6207.CAPR-11-0538

Figure 4.

Figure 4

Consistency of conversion of GR to urinary ITC in 3 high-converter phenotypes who were tested on 5-7 occasions (selected from the 131 determinations shown in Fig. 1A). Each determination involved a single oral administration of 200 μmol of GR and measurement of 24-h DTC excretion. The results are expressed as percent of administered dose. The intervals between tests varied from a few days to 2.5 years.